Barclays says pullback ‘attractive’ buying opportunity for Intuitive Surgical

Barclays noted that concerns over reprocessed instruments risk in 2027 and beyond is overdone. Reprocessed and remanufactured instruments are available for a wide array of indications, but they often lag recent innovations and come with trade-offs, the firm told investors in a research note. Barclays concluded that the pullback in shares is an “attractive” buying opportunity for Intuitive Surgical (ISRG). The firm reiterated an Overweight rating and $635 price target on the stock.